AlphAIAlphAI — Financial news for AI agents
gurufocus.comOCT 212 min read$APLE

APLE Maintained by JP Morgan -- Price Target Raised to $17.00

JP Morgan maintained a 'Neutral' rating for Apple Hospitality REIT (APLE) but raised its price target from $16.00 to $17.00. APLE is currently overvalued by 20.2% according to GF Value™, with a P/E (TTM) of 24.6x. The company has a GF Score™ of 84/100, indicating strong performance. APLE operates upscale hotels under brands like Marriott and Hilton, with a market cap of $4.3 billion.

Original reporting
gurufocus.com
Published Oct 21, 2026, 3:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 3:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$APLE
Bullish
medium confidence
Mentioned
$APLE
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$APLEBullishMed
01

Why it matters

Price target increase suggests slight positive bias but neutral rating tempers market reaction.

02

Market read

Provides fresh analyst target information for APLE, modest trading relevance.

03

What to watch

High valuation metrics (P/E 24.6x) and overvaluation relative to GF value could limit upside.

Relevance 7/10Novelty 7/10Timing: today

Background

Analyst rating update from JP Morgan for Apple Hospitality REIT.

Company-level read

Ticker impact

$APLEBullishMedium confidence
Context

JP Morgan raised APLE's price target to $17, indicating a modest upside view.

Expected impact

likely slight upward pressure as investors price in the higher target

Evidence & confidence

Analyst target increase signals improved outlook but rating remains neutral, limiting upside.

Market effects

Sector

May lift sentiment for REITs focused on upscale hotels.

Regional

Limited to US hospitality REIT space.

Global

Low global impact.

Counterpoint

What could challenge this read

Target raise is modest and rating unchanged; price may stay overvalued.

Key entities

  • company
    Apple Hospitality REIT

    US-listed REIT focusing on upscale hotels.

  • analyst
    JP Morgan

    Maintains neutral rating while raising price target.

Read at source← All news

Related articles

AUG 5
$APLEMed

Apple Hospitality REIT Reports Results of Operations for Second Quarter 2026

Apple Hospitality REIT, Inc. (APLE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Apple Hospitality REIT Reports Results of Operations for Second Quarter 2026 RICHMOND, Va. (August 5, 2026) – Apple Hospitality REIT, Inc. (NYSE: APLE) (the “Company” or “Apple Hospitality”) today announced results of operations for the second quarter ended June 30,

SEC EDGAR 8-K6 min
JUL 17
$PSAMed

REIT ETF RDOG Rides M&A, Refinancing Wave to 22% Gain

RDOG, the ALPS REIT Dividend Dogs ETF, gained 22.1% year to date through July 17, helped by M&A, credit upgrades and refinancings in its holdings. National Storage Affiliates jumped 66.2% after Public Storage agreed to buy it in March. Other contributors included FrontView, Postal Realty and RLJ Lodging. Nareit reported 8 REIT mergers and privatizations worth $57.7B through June.

etftrends.com7 min
OCT 28
$FWRDMed

Forward Air Announces Two-Year Definitive Agreement to Retain Significant Portion of Previously Disclosed Customer Relationship

FORWARD AIR CORP (FWRD) filed an SEC Form 8-K — Other Events. Forward Air Announces Two-Year Definitive Agreement to Retain Significant Portion of Previously Disclosed Customer Relationship 2026 to 2028 Forecasted Annual Revenue from Customer Expected to Exceed 2025 Revenue Driven by Growth in Retained Services DALLAS – October 28, 2026 – F

SEC EDGAR 8-K4 min
OCT 28
$PYPDMedAI 8/10

PolyPid unveils PD01B for diabetic foot infection treatment

PolyPid Ltd. (NASDAQ:PYPD) introduced PD01B, a product candidate for treating moderate to severe diabetic foot infections, using its Kynatrix delivery technology. The company plans to initiate a first-in-human study in the second half of 2027. PolyPid also expects a decision on its lead product D-PLEX₁₀₀ by November 28, 2026, with a potential U.S. launch in early 2027, subject to FDA approval.

investing.com2 min
OCT 28
$KTOSMed

Kratos wins $33.6 million NASA power system contract

Kratos Defense & Security Solutions (KTOS) won a $33.6M contract from NASA to design and build a power system for the Space Reactor-1 Freedom spacecraft, launching in 2028. Kratos will work as a subcontractor to Sierra Lobo under NASA’s SpaceDOC III contract, providing a power conversion system for the mission to Mars. The spacecraft aims to demonstrate nuclear electric propulsion technology. According to the company, the contract is a significant milestone in advancing space nuclear propulsion.

investing.com3 min